Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [60]
According to FDA prescribing information, gastrointestinal side effects are typically most pronounced during dose initiation and escalation, and they often diminish over time as the body adapts to the medication
Effects of dapagliflozin in stage 4 chronic kidney disease
Currently, GLP-1 agonist molecules are also prescribed off-label for obesity conditions
Efficacy of GLP-1 analog peptides, semaglutide, GLP-2 Tirz, and GLP-3 on MC4R deficient obesity and their comparison. International journal of obesity (2005)